{{One needs to recognize that results from cell lines and mouse models very frequently don't replicate in human trials.}}
Looks like your theory was blown out of the Fargo waters.... because who in their right mind aggressively goes after PS Targeting to hold it back as much as possible if things were not replicating in human trials : )
Doubling of MOS says things work just as planned and in Sunrise, all went as expected and expectations were not to run a phase III and not beat SOC
My comment isn't a theory. It is an undeniable fact. Many drugs works very well on cell lines and in mouse models but fail in clinical trials. Bavi is one of the dugs which has illustrated his quite well and quite often. There was no doubling of survival in the small corrupted NSCLC phase II Bavi+Doc trial. As far as Sunrise, it was stopped at the first futility analysis so it sure as hell didn't double MOS of the control arm.
Market Data 
Markets 
AI
